Matt Segall

From Crucible Network Research Projects
Jump to navigationJump to search

Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new design approaches to drug discovery that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.